

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Biocure Technology Inc. (the "Issuer").

Trading Symbol: CURE

Number of Outstanding Listed Securities: 96,793,301

Date: November 5, 2018

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Biocure Technology Inc. has released successful results of the preclinical trial of safety and toxicity of CAR-T-cell-based treatment for acute lymphocytic leukemia.

This is the first breakthrough milestone achieved in Korea and serves as a prerequisite by Korea FDA (KFDA) for proceeding to an IND (investigational new drug) application.

The trial results demonstrated a complete remission of the cancerous cells within seven days and 28 days from the injection of re-engineered CAR-T cells into a mouse. The study further showed encouraging results as no toxicity symptoms have risen from the high-volume injection. The company believes these to be strong indicators for the next phase of clinical trials.

CAR-T cells are a novel form of potential treatment for cancer by enlisting and strengthening the power of a patient's own immune system to attack cancerous tumours. T cells are the fundamental protection agent of the human immune system and plays a critical role in orchestrating the immune response and killing cells infected by pathogens.

CAR-T-cell immunotherapy essentially trains or engineers T cells to recognize specific cancer-related proteins or antigens (CD19 in this case) and thus attach themselves to that cancer cell and destroy it specifically without harming healthy cells. The T cells are taken from the patient's own blood, being re-engineered (or trained) and reintroduced back into the body with their new abilities to fight specific cancerous cells. The training entails a production of new receptors on the T-cell surface that now will enhance the T cell with the ability to recognize/attach itself to the cancerous cell's surface proteins/antigens. These new T-cell receptors are called chimeric antigen receptors (CARs in short), which coined the industry name of this novel treatment to CAR-T.

The trial, first of its kind in the history of Korea, is a result of a wide Korean scientific collaboration. Biocure has performed the trial through its wholly owned subsidiary BiocurePharm in collaboration with Pharos Vaccine with the assistance of Osong Medical Innovation Foundations as the trial CRO (contract research organization) and Croen Corp., which led the toxicity tests under GLP (good laboratory practice) standards.

Biocure has successfully completed the safety test of a biodistribution analysis study and toxicity study for single-dose intravenous injection as per the Korea Food and Drug Administration guidelines. This milestone allows BioCure to advance into the actual production of anti-CD19 CAR-T cell for a clinical trial.

The company has already contracted Cdmogen Co. Ltd. and Master Cell Bank to produce a lentiviral vector under GMP (good manufacturing practice) standards necessary for advancing to the next stage of CAR-T-cell-based clinical trials.

2. Provide a general overview and discussion of the activities of management.

Biocure Technology Inc. has released successful results of the preclinical trial of safety and toxicity of CAR-T-cell-based treatment for acute lymphocytic leukemia.

This is the first breakthrough milestone achieved in Korea and serves as a prerequisite by Korea FDA (KFDA) for proceeding to an IND (investigational new drug) application.

The trial results demonstrated a complete remission of the cancerous cells within seven days and 28 days from the injection of re-engineered CAR-T cells into a mouse. The study further showed encouraging results as no toxicity symptoms have risen from the high-volume injection. The company believes these to be strong indicators for the next phase of clinical trials.

CAR-T cells are a novel form of potential treatment for cancer by enlisting and strengthening the power of a patient's own immune system to attack cancerous tumours. T cells are the fundamental protection agent of the human immune system and plays a critical role in orchestrating the immune response and killing cells infected by pathogens.

CAR-T-cell immunotherapy essentially trains or engineers T cells to recognize specific cancer-related proteins or antigens (CD19 in this case) and thus attach themselves to that cancer cell and destroy it specifically without harming healthy cells. The T cells are taken from the patient's own blood, being re-engineered (or trained) and reintroduced back into the body with their new abilities to fight specific cancerous cells. The training entails a production of new receptors on the T-cell surface that now will enhance the T cell with the ability to recognize/attach itself to the cancerous cell's surface proteins/antigens. These new T-cell receptors are called chimeric antigen receptors (CARs in short), which coined the industry name of this novel treatment to CAR-T.

The trial, first of its kind in the history of Korea, is a result of a wide Korean scientific collaboration. Biocure has performed the trial through its wholly owned subsidiary BiocurePharm in collaboration with Pharos Vaccine with the assistance of Osong Medical Innovation Foundations as the trial CRO (contract research organization) and Croen Corp., which led the toxicity tests under GLP (good laboratory practice) standards.

Biocure has successfully completed the safety test of a biodistribution analysis study and toxicity study for single-dose intravenous injection as per the Korea Food and Drug Administration guidelines. This milestone allows BioCure to advance into the actual production of anti-CD19 CAR-T cell for a clinical trial.

The company has already contracted Cdmogen Co. Ltd. and Master Cell Bank to produce a lentiviral vector under GMP (good manufacturing practice) standards necessary for advancing to the next stage of CAR-T-cell-based clinical trials.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable to the issuer during the month of October 2018

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable to the issuer during the month of October 2018

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable to the issuer during the month of October 2018

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable to the issuer during the month of October 2018

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if

applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship..

Not applicable to the issuer during the month of October 2018

8. Describe the acquisition of new customers or loss of customers.

Not applicable to the issuer during the month of October 2018

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable to the issuer during the month of October 2018

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable to the issuer during the month of October 2018

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable to the issuer during the month of October 2018

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable to the issuer during the month of October 2018

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Other than in relation to accounts payable incurred by the Issuer in the ordinary course of business with its service providers, not applicable to the issuer during the month of October 2018.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
N/A	N/A	N/A	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

Not applicable to the issuer during the month of October 2018

16. Provide details of any changes in directors, officers or committee members.

Not applicable to the issuer during the month of October 2018

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Not applicable to the issuer during the month of October 2018

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 5, 2018.

Konstantin Lichtenwald
Name of Director or Senior Officer

"Konstantin Lichtenwald"
Signature
CFO and Director
Official Capacity

Issuer Details Name of Issuer BIOCURE TECHNOLOGY INC	For Month End October 2018	Date of Report YY/MM/D 18/11/05
Issuer Address 300-1055 West Hastings Street		
City/Province/Postal Code Vancouver BC, V6E 2E9	Issuer Fax No. (604) 685 5120	Issuer Telephone No. (604) 609 7146
Contact Name Konstantin Lichtenwald	Contact Position Director	Contact Telephone No. (604) 609 7146
Contact Email Address klichtenwald@bicuretech.com	Web Site Address www.biocuretech.com	